Candel Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Candel Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.130.130.13
Cost of Revenue0.9923.5920.3514.590.00
Gross Profit-0.99-23.59-20.22-14.470.13
Operating Expenses
Research & Development19.3124.5120.7915.187.94
Selling, General & Administrative14.0614.4114.0610.675.99
Operating Expenses33.3714.4134.8024.7813.94
Operating Income-33.37-38.00-34.67-24.65-13.81
Other Income/Expense
Interest Income1.092.081.220.000.11
Interest Expense2.09-2.601.710.050.00
Other Income/Expense-20.800.9716.37-11.42-3.98
Income
Income Before Tax-55.18-37.94-18.79-36.12-17.68
Income Tax Expense0.000.000.000.000.00
Net Income-55.18-37.94-18.79-36.12-17.68
Net Income - Continuous Operations-55.18-37.94-18.79-36.120.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-52.10-37.04-16.31-24.42-13.72
EBIT-53.09-38.00-17.09-24.65-13.81
Depreciation & Amortization0.990.960.780.230.09
Earnings Per Share
Basic EPS-2.00-1.00-1.00-2.00-2.00
Diluted EPS-2.00-1.00-1.00-2.00-2.00
Basic Shares Outstanding31.6828.9428.8218.8711.62
Diluted Shares Outstanding31.6828.9428.8218.8711.62